91 results about "Estradiols" patented technology

The invention provides a nucleic acid aptamer for specific recognition of morphine and application of the nucleic acid aptamer, and belongs to the technical field of biosensing and detection. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 1. The screening method is based on a Capture-SELEX technology and comprises the key steps that streptavidin magnetic beads are used for fixing an ssDNA library, estradiol, deabietic acid and totarol are introduced to serve as reverse screening substances so as to remove non-specific sequences, and finally the high-specificity aptamer is obtained through high-throughput sequencing and affinity determination. The dissociation constant of the aptamer and morphine is 127.31 nM, and the aptamer shows high affinity and high specificity. The invention further relates to application of the aptamer in preparation of a sensor and a kit for detecting morphine, and a new technical means is provided for rapid detection of morphine.

Provided are methods for determining the amount of estradiol in a sample using mass spectrometry. The methods generally involve ionizing estradiol in a sample and detecting and quantifying the amount of the ion to determine the amount of estradiol in the sample.

The present invention relates to an oral extract composition comprising Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) extract composition, and its process of preparation. Also relates to the oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient for, improvement, and maintenance of women health more preferably in improving of hot flashes, night sweats, poor sleep, anxiety, sexual dysfunction, mood changes, Genitourinary symptoms in overall improving the quality of life, serum estradiol, progesterone, follicle stimulating hormone (FSH), and cortisol during the period of menopause (perimenopause and menopause). The oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient is used for improving Brain-derived neurotrophic factor (BDNF) levels in women during the period of menopause. The present invention, further related to the extraction process of Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.), also provides the process for the preparation of formulation composition. This invention further relates to the extraction process from Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) either as individual herbs or co-extraction of the two herbs or mixing the extracts at various stages of the individual extracts.

The invention discloses an aptamer electrochemical biosensor for estradiol detection as well as a preparation method and application of the aptamer electrochemical biosensor. The aptamer electrochemical biosensor is obtained by growing AuNPs particles on the surface of MoS2 to prepare a MoS2-AuNPs composite material, fixing the composite material on the surface of an electrode through chitosan, hybridizing aptamer probes P1 and P2, and self-assembling the aptamer probes P1 and P2 on the surface of the electrode through Au-S bonds. The sensor can be used for in-situ detection of hormone factor estradiol in sweat, can be applied to non-invasive monitoring equipment, and provides reliable and timely monitoring data.

Provided are methods of contraception using as a first line combined oral contraceptive (COC), a COC composition comprising nomegestrol acetate (NOMAC) and estradiol or an ester thereof. Said COC compositions are associated with a lower risk of venous thromboembolism (VTE) as compared to other CHCs. The compositions may also be used in methods of treatment in women having conditions linked to menstruation and / or fertility.

This invention discloses a method for large-scale breeding of all-male salmon and trout, belonging to the field of fish sex regulation breeding technology. The method includes: collecting fertilized eggs from different families of the same species of salmon and trout, artificially incubating them to obtain fry, and inducing sex reversal in the fry by using 17β-estradiol when they begin feeding; subsequently, raising the fry to sexual maturity, selecting individuals with a female phenotype, and then using sdY as a sex identification gene, selecting pseudo-females with genotype XY by quantitative real-time PCR; pairing the sexually mature pseudo-females with genotype XY with normal males with genotype XY, and obtaining super-males with genotype YY through artificial insemination; pairing the sexually mature super-males with females with genotype XX, and producing all-male salmon and trout with genotype XY on a large scale through artificial insemination. This invention overcomes the problem that existing technologies cannot achieve large-scale breeding of all-male salmon and trout.

This invention belongs to the field of analytical detection technology and relates to a method for detecting estradiol using a combination of organometallic framework enrichment and enzyme-linked immunosorbent assay (ELISA). A magnetic organometallic framework solid-phase extractant is used to enrich estradiol in the sample, followed by detection of the enriched estradiol using ELISA. The magnetic organometallic framework solid-phase extractant is prepared by subjecting mercaptoacetic acid-modified Fe3O4 particles, zirconium salt, and 2-amino-terephthalic acid to a solvothermal reaction at 110–130°C for 22–26 hours. The detection method provided by this invention has advantages such as short detection time, high sensitivity, good specificity, and high accuracy, thereby enabling the detection of trace amounts of estradiol in environmental water samples.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

The invention belongs to the technical field of transdermal patches, and relates to a transdermal patch for improving the bioavailability of estradiol and a preparation method of the transdermal patch. The transdermal patch is prepared from the following components in percentage by weight: 5 to 21 percent of estradiol, 8 to 15 percent of polymer matrix, 0.5 to 1.5 percent of butylated hydroxytoluene, 10 to 15 percent of hydrogenated rosin glyceride, 2 to 5 percent of penetration enhancer, 3 to 8 percent of plasticizer and 25 to 35 percent of solvent. According to the transdermal patch disclosed by the invention, continuous and stable release of a medicine is realized, the transdermal absorption rate of estradiol is improved, so that the bioavailability is improved, the treatment effect is further improved, and meanwhile, the transdermal patch disclosed by the invention can also avoid a first-pass effect of the liver and reduce side effects; the transdermal drug delivery system is convenient to use, and the compliance of a patient is improved.

The application provides an application of a traditional Chinese medicine preparation in preparation of a drug for treating dysmenorrhea, and an active ingredient of the traditional Chinese medicine preparation is prepared from liquorice, asarum, cassia twig, angelica, white peony root, common sage and chuanxiong. The traditional Chinese medicine preparation provided by the application fuses multi-dimensional treatment strategies of warming meridians, nourishing blood, regulating qi and dredging collaterals, and can cover different TCM syndrome types such as cold coagulation and blood stasis, qi stagnation and blood stasis and qi and blood deficiency. Pharmacological experiments show that for dysmenorrhea rats of the cold coagulation and blood stasis type, the traditional Chinese medicine preparation of the application can reduce the sensitivity of the uterus caused by benzoic acid estradiol and inhibit the writhing reaction of the rats caused by oxytocin, which indicates that the traditional Chinese medicine preparation of the application has the effect of treating dysmenorrhea.

Among hospital–acquired infections, Pseudomonas aeruginosa-associated urinary tract infections (UTIs) are mainly caused by indwelling urethral catheters (catheter-associated UTIs or CAUTIs) and are difficult to treat, resulting in high rates of morbidity among hospitalized patients. While antibiotics can successfully treat bacteria in the bladder lumen, they are inefficient at crossing stratified urothelium plasma membranes to kill persistent intracellular bacterial communities (IBCs). Herein, UTI IBCs are targeted by locally delivering the antibiotic gentamicin and / or the steroid hormone estradiol via polymeric nanogels conjugated with a cell-penetrating peptide Cys-Gly-Lys-Arg-Lys (CGKRK - SEQ ID NO:1). This approach delivered more intracellular gentamicin compared to drug delivered in solution in vitro and more estradiol compared to conventional methods. In an acute UTI murine model, the nanogel cell-penetrating peptide drug delivery system facilitated the transport of gentamicin into the urothelium and resulted in > 90% clearance of a uropathogenic P. aeruginosa clinical strain in vivo.

The application relates to the field of biotechnology, and particularly relates to an application of Bacteroides ovatus in ovarian aging; the application comprises: taking low-abundance Bacteroides ovatus as a biomarker of ovarian aging; the application comprises using Bacteroides ovatus in a medicine for delaying ovarian aging; the application further comprises using a fermentation product of Bacteroides ovatus in the medicine for delaying ovarian aging; it is found through experiments that there is a significant difference in Bacteroides ovatus in mice with different degrees of ovarian aging, and it is found through subsequent experiments that Bacteroides ovatus has the effects of significantly increasing the number of oocytes, up-regulating anti-Mullerian hormone, up-regulating the level of estradiol and down-regulating the level of follicle-stimulating hormone, which indicates that Bacteroides ovatus can be used in the medicine for delaying ovarian aging.

The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

This invention belongs to the field of biomedicine and discloses estradiol derivatives or pharmaceutically acceptable salts thereof with the structure shown in Formula I: R is selected from R1, which is selected from F, Cl, Br, and I; L is selected from straight-chain or branched alkyl groups with 2 to 10 carbon atoms. This invention also discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating depression and anxiety. Furthermore, this invention discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs targeting ERβ / SERT for treating depression and anxiety. The estradiol derivatives of this invention can simultaneously and effectively inhibit SERT and activate ERβ, thereby synergistically enhancing serotonergic neurotransmission and regulating neuroplasticity, and enhancing antidepressant efficacy through multi-target synergistic effects.

This application discloses antibodies or antigen-binding fragments thereof that specifically bind to estradiol, immune complexes comprising the same, single-chain antibodies that specifically bind to the immune complexes, methods for their preparation, and uses. The antibody or antigen-binding fragment specifically binding to estradiol comprises a first heavy chain variable region and a first light chain variable region; wherein the first heavy chain variable region comprises first heavy chain CDR1, first heavy chain CDR2, and first heavy chain CDR3, and the first light chain variable region comprises first light chain CDR1, first light chain CDR2, and first light chain CDR3, and each of the six CDRs comprises an amino acid fragment with the sequence shown in SEQ ID NO: 1-6. Applying this antibody or antigen-binding fragment specifically binding to estradiol, along with ScFv selected based on it, to the sandwich method for detecting E2 in serum can significantly reduce background signal and improve the signal-to-noise ratio.

The application discloses an application of a nuclear receptor target gene in preparation of a biological preparation for blocking activation of diapause larvae, and relates to the field of biotechnology and parasite prevention and control. According to two nuclear receptor targets of Haemonchus contortus HCON_00101910 (regulating activity of worms) and HCON_00023750 (regulating development of larvae), the two nuclear receptor targets are combined with host progesterone and estradiol and are activated, constitute a key signal path in the spring activation process of diapause larvae, and have no homologous genes in mammals, and the safety is excellent. By constructing specific shRNA lentivirus vectors (the silencing efficiency is all greater than or equal to 60%) targeting the two genes, single target or double target synergistic intervention is realized, and the activity-development double key links of worms in the host body can be specifically blocked. The application provides a new paradigm of preventive prevention and control with high specificity and green safety, and provides core technical support for solving the seasonal epidemic problem of blood fluke disease.

The invention provides a traditional Chinese medicine composition for preventing hair loss and promoting hair growth and application thereof, and relates to the technical field of hair loss prevention and promoting hair growth, the traditional Chinese medicine composition is composed of Chinese doughnut, cockscomb, albizia flower, Chinese honey locust, schizonepeta, lithospermum, polygonum multiflorum, prepared rehmannia root, notopterygium root, radix angelicae pubescentis, ruddle and periostracum cicada; in-vitro experiments show that the traditional Chinese medicine composition can promote proliferation of human dermal papilla cells HDPC, relieve the damage degree of HDPC and induce cycle transformation of hair follicles, so that the effect of promoting hair growth is achieved; animal experiments show that the traditional Chinese medicine composition can significantly increase the number of hair follicles and the thickness of skin and dermis fat of mice, reduce the levels of mouse serum IL-2, TNF-alpha and TGF-beta1 and reduce the levels of testosterone, dihydrotestosterone and estradiol in mouse skin tissue, so that hair follicle fibrosis is inhibited, the growth period of hair follicles is accelerated, the growth period is prolonged, the hair loss phenomenon is improved, and the hair loss rate is increased. The hair growth is promoted.

The invention provides a product related to non-obstructive azoospermia microscopic sperm extraction, application and a method. The invention discloses application of a reagent for detecting clinical information in preparation of a non-obstructive azoospermia microscopic sperm extraction product. The clinical information comprises age, testis size, testosterone, estradiol E2, androgen T, follicle stimulating hormone FSH, statin B and seminal plasma cell-free DNA motif diversity score. The prediction method comprises the following steps: acquiring clinical information of a to-be-tested object; inputting the clinical information into a prediction model based on machine learning to obtain a probability P of successful microscopic sperm extraction; and according to comparison between the probability P and a reference value, diagnosing or predicting whether the to-be-detected object is suitable for microscopic sperm collection. The prediction method provided by the invention can be used for improving the accuracy of predicting the success rate of microscopic sperm extraction of non-obstructive azoospermia, and has a relatively good clinical application value.

The application belongs to the technical field of plant genetic engineering and genetic breeding, and particularly relates to a method for improving regeneration and genetic transformation efficiency of peanut plants by ectopic expression of a gene AhLEC1a The application discloses a method for improving regeneration efficiency and genetic transformation success rate of peanut plants by ectopic expression of a gene AhLEC1a The method is characterized in that a beta-estradiol inducible expression vector is constructed AhLEC1a The transgenic plants are obtained by using somatic embryo regeneration or a direct organ regeneration approach. AhLEC1a The ectopic expression of the gene can significantly improve somatic embryo induction rate (up to 100%) and the number of cells of a single explant (2.13 times of that of a control group); the explant bud induction efficiency of the direct organ regeneration approach is improved by 22% compared with that of the control group; and the transgenic positive rates of the two methods are improved by 27.81% and 6.15% respectively compared with those of the control group. The application breaks through the difficulties of low regeneration efficiency and low transformation success rate in peanut genetic transformation, and provides important technical support for peanut gene function research and molecular breeding.

The invention relates to the field of efficient breeding of animals, in particular to a sheep estrus synchronization kit based on follicular wave induction and turnover, application and a use method. The kit contains estradiol benzoate, vitamin ADE, a GnRH analogue buserelin, a progesterone vaginal sustained-release agent, pregnant mare serum gonadotropin and a prostaglandin F2alpha analogue cloprostol sodium according to time nodes, and is matched with instructions for use. According to the method, follicle waves are induced or reset through estrogen and vitamin ADE on the 0th day, buserelin is injected on the 5th day, a progesterone sustained-release agent is placed, follicle development is synchronized, thrombus is removed on the 12th day, PMSG and cloprostenol sodium are jointly injected, follicle final maturation and ovulation are triggered, and estrus testing and mating are conducted 12-96 h after thrombus is removed. According to the scheme, high oestrus rate and highly concentrated oestrus time windows can be obtained for milk goats in different physiological states in the breeding season and the non-breeding season, regular artificial insemination can be conveniently implemented, and the breeding efficiency of a large-scale sheep farm is improved.

The invention relates to the technical field of livestock breeding biology, and discloses a method for promoting porcine ovary granular cell proliferation, which comprises the following steps: adding a porcine follicular fluid exosome into a porcine ovary granular cell culture system, and acting for a certain time at an effective concentration, so as to improve the proliferation activity of granular cells. After the exosome treatment, the apoptosis rate of granular cells can be reduced, the cell survival rate can be improved, and the granular cells can be promoted to secrete steroid hormones, including the estradiol level and the expression of progesterone synthetase. Cell experiments prove that the follicular fluid exosome can effectively improve the activity of granular cells, promote the process of a cell cycle, inhibit cell apoptosis and remarkably enhance the synthesis capacity of steroid hormones such as estradiol and progesterone, and a new intervention strategy is provided for improving follicular development and reproductive performance of sows.

Novel chemical agents are described herein. More specifically, a novel inhibitor of 17β-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In a particular embodiment, the inhibitor of 17β-HSD7 has the following structure: (Formula I) A process for producing the novel inhibitors of 17β-HSD7 and their use in the manufacture of pharmaceutical formulations and / or combinations is also disclosed.

The invention discloses an estradiol valerate film-coated tablet and a preparation method thereof. The estradiol valerate film-coated tablet comprises the following components in parts by weight: 1 part of estradiol valerate, 60-80 parts of a filler, 10-25 parts of a disintegrating agent, 5-12 parts of an adhesive, 1-3 parts of a flow aid, 1-3 parts of a lubricant and 8-14 parts of a film coating premix, and the filling agent is anhydrous lactose. After a sugar coating is changed into a film coating, the front end of the preparation is obviously and quickly dissolved out and is not similar to the original sugar-coated tablet, the tablet core is disintegrated in a corrosion manner by adjusting the dosage of lactose in the prescription, and the whole dissolution of the tablet is similar to the dissolution of the original sugar-coated tablet by adjusting the weight increment of the film coating. The process is simple, industrial production is facilitated, and the stability of the preparation is obviously improved.

This invention belongs to the field of biosensor technology, specifically relating to a method for fabricating and applying a 17β-estradiol photoelectric-electrochemical dual ratio sensor based on a splitting aptamer. The invention designs an assembly of multiple probes at a single sensing interface. The splitting aptamer forms a sandwich structure to synergistically recognize 17β-estradiol and triggers HCR anchoring of CdTe QDs, further adsorbing MB; [Fe(CN)6]. 3‑ / 4‑ The probe outputs a redox current (denoted as I). [Fe(CN)6] 3‑ / 4‑ As a reference signal, MB acts as a dual-function probe to generate I. MB The redox current is denoted as I MB And sensitize and amplify the photocurrent (I) of CdTe QDs PEC ); through I MB / I [Fe(CN)6] 3‑ / 4‑ and I PEC / I [Fe(CN)6] 3‑ / 4‑ Dual ratio signals enable sensitive and accurate analysis of 17β-estradiol in natural water bodies.

The invention discloses a non-alcoholic fatty liver biomarker composition and application thereof, and belongs to the technical field of non-alcoholic fatty liver detection. The non-alcoholic fatty liver biomarker composition comprises at least two of citric acid, linoleic acid, L-glutamic acid, L-glycine, asparaginic acid, progesterone, testosterone and uric acid, and further, the hepatic fibrosis biomarker further comprises at least one of 2-hydroxyestradiol, L-citrulline, L-procholecin, N-acetyl-L-methionine and flavin. The biomarker composition is stable, the possibility of misdiagnosis and missed diagnosis of diseases is greatly reduced, and compared with a single omics analysis method, the biomarker composition is more suitable for the occurrence and development mechanism of the diseases.

The invention belongs to the field of quantitative analysis of drug concentration of a cell lysis solution, and particularly discloses a method for detecting estradiol 17 beta-D glucuronic acid (Estradil 17-(beta-D-Glucuronide)) in the cell lysis solution. According to the method, the concentration of the estradiol 17 beta-D glucuronic acid in the cell lysis buffer can be accurately quantified through specific sample treatment and liquid chromatography and mass spectrometry conditions, the sensitivity is high, the detection limit is low, a novel method capable of being practically popularized and applied is provided for pharmacokinetic research of the estradiol 17 beta-D glucuronic acid, and the method has popularization and application values.